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Purpose: It has been reported that daily recombinant human growth hormone 
(GH) treatment showed beneficial effects on growth in prepubertal children with 
idiopathic short stature (ISS). The present study aimed to validate the GH (Eutro-
pin®) effect on growth promotion and safety after short-term GH treatment. Mate-
rials and Methods: This study was an open-label, multicenter, interventional 
study conducted at nine university hospitals in Korea between 2008 and 2009. 
Thirty six prepubertal children with ISS were enrolled in this study to receive 
6-month GH treatment. Yearly growth rate, height standard deviation score (SDS), 
and adverse events were investigated during treatment. Results: After 26 weeks of 
GH treatment, the height velocity significantly increased by 6.36±3.36 cm/year 
(p<0.001). The lower end of one-sided 95% confidence interval was 5.22 cm/year, 
far greater than the predefined effect size. The gain in height SDS at week 26 was 
0.57±0.27 (p<0.0001). Bone age significantly increased after GH treatment, how-
ever, bone maturation rate (bone age for chronological age) showed limited ad-
vancement. This 26-week GH treatment was effective in increasing serum levels 
of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-3 from 
baseline (p<0.0001). Eutropin was well tolerated and there were no withdrawals 
due to adverse events. No clinically significant changes in laboratory values were 
observed. Conclusion: This 6-month daily GH treatment in children with ISS 
demonstrated increased height velocity, improved height SDS, and increased IGF-
I and IGFBP-3 levels with a favorable safety profile.
Key Words:   Treatment outcome, safety, growth hormone, child, short stature, id-
iopathic
INTRODUCTION
Short stature is one of the most common causes of referral to pediatric endocrinol-
ogist. It is defined as a condition when height is more than 2 standard deviation 
score (SDS) below the corresponding mean height for a given age, gender, and a 
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efficacious for increasing height SDS without any adverse 
effects.  
MATERIALS AND METHODS
　　　
Subjects
Short children with ISS whose chronological age (CA) was 
5 years or older, with a corresponding bone age (BA) of no 
more than 10 years in girls and no more than 12 years in 
boys were included. Inclusion criteria were short stature, 
defined as height less than 3rd percentile for age and gender 
according to the Korean population-based reference;8 peak 
GH responses using one of three GH stimulation tests (cloni-
dine, insulin, or L-dopa) greater than 7 ng/mL (considered a 
normal GH level in children); prepubertal stage according 
to Tanner stage criteria based on breast development in girls 
and testicular volume in boys; no previous GH treatment at 
least within 6 months; children with normal thyroid hor-
mone level (normal thyroid hormone level through hormone 
therapy inclusive); no significant chronic diseases, chromo-
somal abnormalities, skeletal dysplasia, dysmorphic syn-
dromes, short children born small for gestational age, and 
taking any drug suspected to interfere with GH secretion or 
action. Children on hormone therapy such as estrogen, an-
drogen, anabolic steroid, corticosteroid, and methylphenidate 
that could interfere with growth were excluded from the 
study. In total, 36 children with ISS were enrolled into the 
study, and 3 children were not included for the efficacy anal-
ysis, primarily owing to protocol violations. Data from 33 
children with at least one available treatment efficacy data 
were included in the efficacy analysis (full analysis set, FAS). 
The FAS was defined as dataset from those who received at 
least one dose of the study drug and who had at least one 
post-dose auxological measurement. Children with major 
protocol violations, such as poor study drug compliance (less 
than 70%), violations of eligibility criteria, and pubertal ad-
vance during the study were excluded from FAS. Per-proto-
col set (PPS) comprised of 25 children who had followed 
most of the protocol procedures was the main population for 
efficacy presentation. Safety data analyses were performed 
on a safety set that comprised of data from all randomized 
patients who received at least one dose of the study drug. The 
study protocol was approved by the Ethical Committees of 
the participating institutions and Korean FDA. Informed 
consents were obtained from parents or legal guardians of 
each child and from all appropriately aged children. 
population group. Although the causes of short stature have 
been identified in some children, a large number of such 
children remain without a definitive diagnosis and are con-
sidered as having idiopathic short stature (ISS). Therefore, 
ISS can be diagnosed after excluding the evidence of sys-
temic, endocrine, nutritional, or chromosomal abnormali-
ties at the end of the diagnostic evaluation.1 ISS represents 
a heterogeneous group of children having many unidenti-
fied causes of short stature, such as constitutional delay in 
growth and puberty, familial short stature, neurosecretory 
dysfunction, and disorders with gene mutation for mole-
cules involved in growth process in any level including bio-
inactive growth hormone (GH), partial GH insensitivity, 
GH receptor signaling defects, mutations of the insulin-like 
growth factor (IGF)-I or IGF-I receptor, and short stature 
homeobox-containing gene (SHOX) haploinsufficiency. It 
is estimated that approximately 60-80% of all short chil-
dren have a diagnosis consistent with ISS.2 
Recombinant human GH has been used since the approv-
al by US Food and Drug Administration (FDA) to use in 
children with growth failure due to GH deficiency in 1985. 
The indications for GH treatment have gradually extended 
from GH deficiency to non-GH deficient short stature, such 
as chronic renal insufficiency, Turner syndrome, Prader-Willi 
syndrome, short children born small for gestational age 
(SGA), ISS, and Noonan syndrome.3 GH treatment for chil-
dren with ISS was approved in the United States in 2003. 
Such an approval of GH treatment for ISS was based on the 
efficacy results obtained from the randomized studies, sug-
gesting that GH treatment tends to increase the adult height 
of children with ISS by about 4-6 cm.4-6 They recommend-
ed GH treatment (at doses up to 53 μg/kg·d) for children 
with ISS shorter than -2.25 SDS (1.2 percentiles), associat-
ed with height velocity unlikely to permit attainment of 
adult height in the normal range. More recently, a consen-
sus statement of the Growth Hormone Research Society, 
the Lawson Wilkins Pediatric Endocrine Society, and the 
European Society for Pediatric Endocrinology proposed 
that children with ISS whose heights were less than -2 to -3 
SDS warranted consideration for treatment.7 The consensus 
statement also reported that GH therapy can increase the 
adult height in children with ISS by 3.5-7.5 cm (mean treat-
ment of 4-7 years), and has a similar safety profile to other 
GH indications.7 
The aim of this study was to investigate the efficacy and 
safety of short-term GH treatment in prepubertal children 
with ISS to evaluate whether short-term GH therapy was 
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dren and adolescents.8 
Adverse event rates were summarized by System Organ 
Class MedDRA (a registered trademark of the International 
Federation of Pharmaceutical Manufacturers Associations) 
thesaurus terminology (http://www.meddramsso.com). In-
vestigators were instructed to report any adverse clinical or 
laboratory findings when there was a suspicion that GH 
treatment may have been related to the adverse events. 
Statistical analyses
The statistical analyses were performed using the standard 
statistical package SPSS, version 15.0 (SPSS Inc., Chicago, 
IL, USA). Results were expressed as mean±SD unless oth-
erwise specified. Descriptive statistics were used to sum-
marize baseline characteristics, adverse events, and labora-
tory results. Efficacy analyses were performed using paired 
t-test or Wilcoxon’s signed rank test to detect the difference 
from baseline. Differences in laboratory results from base-
line were determined using paired t-test or Wilcoxon’s signed 
rank test. Differences in laboratory values, separately ana-
lyzed in normal and abnormal range group, were deter-
mined using McNemar’s test. We considered a p value less 
than 0.05 to be statistically significant. 
RESULTS
 
Baseline characteristics
Total of 36 subjects with confirmed ISS were enrolled in the 
study, and 33 subjects were included in the FAS and 25 in 
Methods
This study was an open-label, multicenter, interventional 
study. After evaluating growth status during a 6-month pre-
study period, eligible children were given subcutaneous in-
jections of GH with a dose of 0.37 mg/kg/week for 26 weeks, 
dividing equally to be given for 6 consecutive days per week. 
GH (Eutropin®) was provided by LG Life Sciences Ltd. 
(Seoul, Korea). Subjects were required to visit the investiga-
tional site three times including baseline, week 13 and week 
26 to measure height, weight, IGF-I, IGF binding protein 
(IGFBP)-3, thyroid function, hemoglobin A1C and other 
laboratory test items. Peak plasma GH levels after GH 
stimulation test using insulin, clonidine, or L-dopa ranged 
from 14.82 ng/mL to 22.52 ng/mL (Table 1). Pubertal stage 
was also evaluated by pediatric endocrinologist at every 
visit. The measurements of X-ray of left wrist for BA deter-
mination and GH antibody were performed both at baseline 
and week 26. BA was determined in one investigational site 
by Greulich-Pyle method. Telephone calls were made by 
investigational site staff or investigators at week 5 and week 
18 to ensure treatment adherence and to investigate the ad-
verse events.
Two outcome variables were used for efficacy analyses: 
1) mean change in height velocity at week 13 and week 26 
during 6-month treatment with GH; 2) gain in height SDS 
at week 13 and week 26 during 6-month treatment with 
GH. Annualized height velocities are expressed as centime-
ters per year, computed as the change in height (centime-
ters) divided by the change in age (years). The height SDS 
was calculated using the growth standard for Korean chil-
Table 1. Baseline Demographic Data and Laboratory Values
Category FAS (n=33) PPS (n=25)
Baseline demographic data
    Male/Female 16 (48%)/17 (52%) 12 (48%)/13 (52%)
    Chronological age (yrs)     7.9±1.9     8.1±1.9
    Bone age (yrs)     6.9±1.7     7.0±1.8
    Height (cm) 114.6±9.3 115.7±9.3
    BA/CA     0.84±0.16     0.83±0.16
    Height SDS for CA    -2.35±0.53    -2.39±0.54
    Body mass index (kg/m2)   15.95±1.74   16.14±1.94
    Pretreatment height velocity (cm/yr)     4.55±2.01     4.49±1.98
Laboratory values         
    Peak GH level (ng/mL) by ITT     14.82±10.9*    15.51±9.85†
    Peak GH level (ng/mL) by CLT    14.89±7.56‡      15.1±8.55§ 
    Peak GH level (ng/mL) by LdoT      22.52±18.68||        21.5±19.04¶ 
FAS, full analysis set; PPS, per-protocol set; BA, bone age; CA, chronological age; GH, growth hormone; ITT, insulin stimulation test; CLT, clonidine test; LdoT, 
L-dopa test; SDS, standard deviation score.
*n=32, †n=24, ‡n=19, §n=15,  ||n=13, ¶n=10.
Ho-Seong Kim, et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 1   January 201456
the PPS (Fig. 1). All of the enrolled subjects who received at 
least one dose of GH were included in the safety analysis. 
Baseline demographics of FAS and PPS are presented in Ta-
ble 1. Both genders were evenly distributed and subjects’ 
age ranged from 5 to 12 years. Mean BA was delayed about 
one year, compared to mean CA. Only one subject had pre-
vious history of GH treatment in the FAS while PPS com-
prised of only treatment naïve subjects. Height SDS for CA 
was -2.35±0.53 in the FAS and -2.39±0.54 in the PPS. 
Efficacy results
Mean growth velocities at baseline, week 13, and week 26 
were 4.49±1.98, 11.67±4.20, and 10.85±2.34 cm/yr, respec-
tively. After 26 weeks of treatment with GH, significant in-
crease in height velocity by 6.36±3.36 cm/year, compared 
to the baseline value, was observed (p<0.001) (Fig. 2, Table 
2). The gain in height SDS was 0.33±0.23 at week 13 (p< 
0.0001) and 0.57±0.27 at week 26 (p<0.0001) (Fig. 3). These 
results demonstrated the rapid growth enhancement during 
GH treatment, indicating that even the short-term GH treat-
ment can have stimulatory effect on growth. BA also in-
creased after treatment and the mean difference at week 26, 
compared to baseline, was 0.31±0.38 yr, which was a signifi-
cant change (p=0.0005) (Table 2). However, BA was not too 
advanced for CA as bone maturation rate (change in BA/
change in CA) was 0.58±0.72. Serum IGF-I level almost 
doubled at week 26 compared to baseline (150.4±67.8 ng/
mL at baseline vs. 290.0±110.4 ng/mL at week 26; p< 
0.0001). Serum IGFBP-3 level also significantly increased 
after treatment of GH (2442.9±521.8 ng/mL at baseline vs. 
3368.8±685.6 ng/mL at week 26; p<0.0001) (Table 2). 
Those subjects whose IGF-I or IGFBP-3 levels at baseline 
were less than the lower limit of normal range achieved nor-
mal levels of IGF-I and IGFBP-3 at week 26. Analyses us-
Fig. 1. Subject distribution. FAS, full analysis set; PPS, per-protocol set.
Fig. 2. Mean height velocity (cm/year). Data from per-protocol set; error bar 
indicates standard deviation. *Significant change from baseline (p<0.0001, 
Wilcoxon’s signed rank test). **Significant change from baseline (lower 
end of one-sided 95% confidence interval=5.21 cm/year>2 cm/year).
Fig. 3. Mean height SDS and change in height SDS. Data from per-protocol 
set. *Significant change from baseline (p<0.0001, Wilcoxon’s signed rank 
test). SDS, standard deviation score. 
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pruritus on injection site that was reported twice in a same 
subject was assessed as being related to the study drug and 
it was resolved without any intervention. No serious ad-
verse events were reported and no withdrawals due to ad-
verse events. No clinically significant changes in laboratory 
values were observed except overall increase in alkaline 
phosphatase (308.08±202.54 IU/L at baseline vs. 436.26± 
290.60 IU/L at week 26; p<0.0001), which was considered 
to be associated with bone growth after administration of 
GH (Table 2). Statistically significant increase in the num-
ing FAS on these efficacy parameters yielded similar results 
(data not shown).
Safety results
Among total 36 subjects, 23 (63.89%) children reported 65 
adverse events (Table 3 and 4). The most common adverse 
event was nasopharyngitis (35.38%, 23 events among 65 
events), which was reported in 12 children, and it was a fre-
quently expected adverse event in the study population. All 
the remaining adverse events were mild in intensity. Mild 
Table 2. Anthropometric, Radiologic and Laboratory Results during Growth Hormone Treatment in Per-Protocol Set
Baseline Wk 13 Wk 26
Height velocity (cm/yr)    4.49±1.98   11.67±4.20*   10.85±2.34*
Height SDS for CA  -2.39±0.54  -2.06±0.61†   -1.82±0.59† 
BA (yrs)    7.00±1.78 -    7.31±1.60‡ 
BA/CA    0.83±0.16 -     0.81±0.14*
ΔBA/ΔCA - -   0.58±0.72
IGF-I (ng/mL)  150.43±67.83    264.92±110.51†    289.98±110.40† 
IGFBP-3 (ng/mL)  2442.90±521.78   2982.60±552.58*   3368.80±685.63* 
ALP (IU/L)    308.08±202.54    413.44±282.05†    436.26±290.60† 
Total chol (mg/dL)  167.44±25.28 161.88±27.62 163.94±25.11
Triglyceride (mg/dL)    80.17±49.11   93.88±44.03   94.29±50.52
HDL-chol (mg/dL)    59.47±13.03   56.19±12.51   57.68±10.63
LDL-chol (mg/dL)    93.76±21.28   88.24±23.24   88.83±21.76
Fasting glucose (mg/dL)    88.78±11.06   96.28±9.36*    92.37±17.61§
HbA1C (%)    5.28±0.27    5.49±0.29 ||     5.45±0.23* 
Free T4 (ng/dL)    1.37±0.19  1.26±0.20   1.37±0.18
TSH (mIU/L)    3.11±2.36  3.26±2.21   2.36±1.16
Postive anti-hGH Ab 0/35 (0%) - 3/32 (9%)
SDS, standard deviation score; BA, bone age; CA, chronological age; IGF-I, insulin-like growth factor-I; IGFBP-3, IGF binding protein-3; ALP, alkaline phos-
phatase; chol, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; HbA1C, hemoglobin A1C; TSH, thyroid stimulating hormone.   
*p<0.0001 by paired t-test. 
†p<0.0001 by Wilcoxon’s signed rank test. 
‡p=0.0005 by Wilcoxon’s signed rank test. 
§p=0.0011 by Wilcoxon’s signed rank test. 
 ||p=0.0010 by paired t-test. 
Table 3. Adverse Events by System Organ Class 
System organ class Number of subjects (n=36) Number of events (n=65)
Endocrine disorders 1 (2.78) 1 (1.54)
Eye disorders 2 (5.56) 2 (3.08)
Gastrointestinal disorders   6 (16.67)   7 (10.77)
General disorders and administration site conditions 3 (8.33) 4 (6.15)
Infections and infestations 18 (50.00) 41 (63.08)
Musculoskeletal and connective tissue disorders 3 (8.33) 3 (4.62)
Nervous system disorders 2 (5.56) 2 (3.08)
Respiratory, thoracic and mediastinal disorders 1 (2.78) 1 (1.54)
Skin and subcutaneous tissue disorders 3 (8.33) 3 (4.62)
Vascular disorders 1 (2.78) 1 (1.54)
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of treatment.11,12 The acceleration of height velocity after 
GH treatment is more prominent at a higher dosage (50 μg/
kg/day) than that at a dosage close to a replacement dosage 
(25 μg/kg/day).13 These results suggest that children with 
ISS may not have sufficient endogenous GH secretion to 
overcome decreased GH sensitivity, therefore, a larger re-
placement dose of GH results in more increase of the growth 
response. Studies about the short-term height gains have 
shown that the change in height SDS can range from none 
to approximately 0.7 SDS over one year.9 In the present 
study, GH treatment for 6-month increased yearly height 
velocity by 6.36 cm/yr, as well as gain in height SDS by 
0.57, suggesting that short-term GH treatment in prepuber-
tal children with ISS affects on growth promotion. More-
over, increase in the height velocity and gain in height SDS 
observed by week 13 revealed stimulatory effect of GH 
treatment occurring even earlier. 
In the present study using GH dosage of 0.37 mg/kg/
week (61.7 μg/kg/day), no effect was observed on BA ad-
vancement. Previous studies using approximately 30-50 
μg/kg/day of GH have also shown that GH does not influ-
ence the rate of BA advancement.6,14,15 However, one ran-
domized controlled study using GH with a dosage of 70 μg/
kg/day has demonstrated a significant advancement of BA 
and onset of puberty, suggesting that a higher dosage of GH 
may accelerate bone maturation and onset of puberty.16 For 
these reasons, it is suggested that GH dose of 50 μg/kg/day 
might be closer to the optimum dosage for ISS treatment, 
and the regulatory authority in the United States has ap-
proved GH treatment at doses up to 0.3-0.37 mg/kg/week 
(50-61.7 μg/kg/day) for children with ISS shorter than -2.25 
SDS.17 On the other hand, one study adjusting the GH dos-
age according to the serum level of IGF-I showed no change 
in BA advancement and pubertal development even at high-
er dose (mean GH dose of 110 μg/kg/day), suggesting a 
large individual variability in this matter.18 
Several studies have proved that GH can increase the fi-
nal adult height in children with ISS. The adult height of 
children with ISS after GH treatment for 4-7 years was av-
erage 3.7-7.5 cm taller than untreated or placebo-treated 
controls.9,19 Adult height SDS was also significantly greater 
in the GH treated group (-1.77±0.17 SDS) than in the pla-
cebo-treated group (-2.34±0.17 SDS) by 0.57 SDS.9 The ef-
fect of GH on adult heights in children with ISS is known 
to be similar to that of Turner syndrome, or GH deficiency, 
and similar or slightly less than that in children born SGA.19 
The growth response to GH is highly variable, and may be 
ber of children with abnormally high density lipoprotein at 
week 13 was observed [8 (22%) children at baseline vs. 13 
(41%) children at week 13; p=0.0253], however, this change 
was not clinically significant as other lipid profiles were 
within normal ranges (Table 2). All 35 children tested for 
GH antibody at baseline showed negative responses, while 
3 (9.4%) children out of 32 tested for antibody at week 26 
showed positive responses without deteriorating effect on 
growth (Table 2). 
DISCUSSION
In the present study, we showed that the daily administra-
tion of GH in prepubertal children with ISS resulted in a 
marked increase in the mean height velocity during the 6 
month-treatment period. Yearly height velocity increased 
by 6.36 cm/yr after GH treatment (from 4.49 cm/yr at base-
line to 10.85 cm/yr at week 26). The accelerated height ve-
locity resulted in significant increase in height SDS for CA 
by 0.57±0.27 during 6-month treatment (from -2.39 at base-
line to -1.82 at week 26). Moreover, height SDS for BA was 
also increased during the treatment, suggesting that GH 
treatment might lead to improved ultimate stature without 
inducing advanced bone maturation. Proper bone matura-
tion after GH treatment with a dose of 0.37 mg/kg/week 
was also supported by the finding that bone maturation rate 
was 0.58±0.72. 
Recent reviews about the results of GH therapy for ISS 
showed that GH treatment can increase short-term growth 
and improve final adult height.9,10 Several clinical trials have 
reported that GH treatment for ISS increases height veloci-
ty in the first year, followed by gradual tapering off in subse-
quent years. Overall, mean height velocity increased from 
4-5 cm/year before treatment to 8-9 cm/year in the first year 
Table 4. Frequent Adverse Events (≥5% of the Subjects) by 
Preferred Term
Preferred term
Number of 
subjects (n=36)
Number of 
events (n=65)
Abdominal pain   4 (11.11) 4 (6.15)
Hordeolum 2 (5.56) 2 (3.08)
Nasopharyngitis 12 (33.33) 23 (35.38)
Otitis media 3 (8.33) 4 (6.15)
Upper respiratory 
  tract infection
3 (8.33) 6 (9.23)
Pain in extremity 2 (5.56) 2 (3.08)
Urticaria 2 (5.56) 2 (3.08)
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creased risk of breast, prostate, lung and colon cancer.24 Re-
cently, preliminary report of the French Safety and Appropri-
ateness of Growth hormone treatments in Europe (SAGhE) 
study demonstrated that mortality rates were increased in 
adults treated with GH as children. Particularly, those who 
had received the highest doses showed increased bone tu-
mors or cerebral hemorrhage but not for all cancers.25 How-
ever, these results are not yet conclusive and still in debate. 
The French SAGhE study recommended to secure proper 
dose (50 µg/kg/day) and continued surveillance through a 
registry and to perform long-term follow-up studies of GH-
treated patients. In addition, there are many ongoing debates 
about the indications for therapy, psychosocial benefit, im-
provement of quality of life, and cost issues in the treatment 
of GH for children with ISS.19 
Despite the limiting factors such as small number of sub-
jects, uncontrolled study, and short-term treatment duration, 
the present study demonstrated the efficacy of GH (Eutro-
pin with a dose of 0.37 mg/kg/week) in children with ISS by 
showing significant increases in height velocity, height SDS, 
and serum levels of IGF-I and IGFBP-3 with favorable 
safety. Nevertheless, further long-term assessment and sur-
veillance for GH-treated children with ISS are warranted.
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